Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-22-011142
Filing Date
2022-05-05
Accepted
2022-05-05 16:46:26
Documents
82
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q pbyi20220331b_10q.htm   iXBRL 10-Q 1130736
2 EXHIBIT 10.1 ex_346524.htm EX-10.1 17397
3 EXHIBIT 31.1 ex_346525.htm EX-31.1 8206
4 EXHIBIT 31.2 ex_346526.htm EX-31.2 8205
5 EXHIBIT 32.1 ex_346527.htm EX-32.1 4963
6 EXHIBIT 32.2 ex_346528.htm EX-32.2 4981
  Complete submission text file 0001437749-22-011142.txt   6957563

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA pbyi-20220331.xsd EX-101.SCH 71167
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE pbyi-20220331_cal.xml EX-101.CAL 62876
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE pbyi-20220331_def.xml EX-101.DEF 459028
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE pbyi-20220331_lab.xml EX-101.LAB 424900
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pbyi-20220331_pre.xml EX-101.PRE 494491
76 EXTRACTED XBRL INSTANCE DOCUMENT pbyi20220331b_10q_htm.xml XML 1093079
Mailing Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024
Business Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024 (424) 248-6500
PUMA BIOTECHNOLOGY, INC. (Filer) CIK: 0001401667 (see all company filings)

EIN.: 770683487 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35703 | Film No.: 22897219
SIC: 2834 Pharmaceutical Preparations